Landos Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of safer and more effective first-in-class oral therapeutics for patients with autoimmune diseases, announced that the Chairman and CEO, Dr. Josep Bassaganya-Riera, will present a company update at the following conferences:
Cowen and Company 39th Annual Healthcare Conference Tuesday, March 12th at 11:00 a.m. ET Webcast: http://wsw.com/webcast/cowen52/lans/
Needham & Company 18th Annual Healthcare Conference Tuesday, April 9th at 11:40 a.m. ET Webcast: http://wsw.com/webcast/needham90/lans/
BioCentury Future Leaders in Biotech Conference Friday, April 12th
The Cowen and Needham presentations will be webcast live at the links shown above and will be archived following the presentation on the Landos website.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
As we continue to build our financial position, we are excited to present Landos therapeutic development pipeline for autoimmune diseases and clinical development program in inflammatory bowel disease (IBD) at these important investment conferences, said Dr. Josep Bassaganya-Riera, Chairman and CEO. Our lead compound, BT-11 is a first-in-class, oral, gut-restricted, investigational new drug for Crohns Disease (CD) and Ulcerative Colitis (UC) that has the potential to disrupt the current IBD treatment paradigm and address an unmet clinical need for safer and more effective oral therapeutics for IBD. We completed our Phase 1 clinical trial in 2018 and initiated our global Phase 2 program for UC in the US and Europe.
About Landos Biopharma Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company has completed Phase 1 clinical testing and initiated a Phase 2 clinical program for BT-11 for treatment of UC and CD in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which will advance to IND in 2019. Landos is headquartered in Blacksburg, VA. For more information, please visit www.landosbiopharma.com or contact [email protected] or follow us @Landosbio.
For Media Requests: